Adjuvant Immunotherapy Atezolizumab Approved for Lung Cancer
By Rachel Ernst |
The FDA has granted approval for atezolizumab as adjuvant immunotherapy for non-small cell lung cancer treatment. Atezolizumab is the first immunotherapy drug to be approved by the FDA for use as an adjuvant indication.
